JP2022521390A - 術後有害事象の診断または予後 - Google Patents

術後有害事象の診断または予後 Download PDF

Info

Publication number
JP2022521390A
JP2022521390A JP2021548207A JP2021548207A JP2022521390A JP 2022521390 A JP2022521390 A JP 2022521390A JP 2021548207 A JP2021548207 A JP 2021548207A JP 2021548207 A JP2021548207 A JP 2021548207A JP 2022521390 A JP2022521390 A JP 2022521390A
Authority
JP
Japan
Prior art keywords
level
sample
fragment
hours
surgery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021548207A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022521390A5 (https=
JPWO2020169819A5 (https=
Inventor
ミシェレ チュー
ヘンリク アンデション
ダライアス ウィルソン
Original Assignee
ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング
リンシェーピング ユニバーシティ ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング, リンシェーピング ユニバーシティ ホスピタル filed Critical ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2022521390A publication Critical patent/JP2022521390A/ja
Publication of JP2022521390A5 publication Critical patent/JP2022521390A5/ja
Publication of JPWO2020169819A5 publication Critical patent/JPWO2020169819A5/ja
Priority to JP2024181817A priority Critical patent/JP2025019061A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021548207A 2019-02-21 2020-02-21 術後有害事象の診断または予後 Pending JP2022521390A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024181817A JP2025019061A (ja) 2019-02-21 2024-10-17 術後有害事象の診断または予後

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19020082 2019-02-21
EP19020082.4 2019-02-21
PCT/EP2020/054652 WO2020169819A1 (en) 2019-02-21 2020-02-21 Diagnosis or prognosis of postsurgical adverse events

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024181817A Division JP2025019061A (ja) 2019-02-21 2024-10-17 術後有害事象の診断または予後

Publications (3)

Publication Number Publication Date
JP2022521390A true JP2022521390A (ja) 2022-04-07
JP2022521390A5 JP2022521390A5 (https=) 2023-03-01
JPWO2020169819A5 JPWO2020169819A5 (https=) 2023-03-01

Family

ID=65529223

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021548207A Pending JP2022521390A (ja) 2019-02-21 2020-02-21 術後有害事象の診断または予後
JP2024181817A Pending JP2025019061A (ja) 2019-02-21 2024-10-17 術後有害事象の診断または予後

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024181817A Pending JP2025019061A (ja) 2019-02-21 2024-10-17 術後有害事象の診断または予後

Country Status (7)

Country Link
US (1) US20220187313A1 (https=)
EP (1) EP3928099A1 (https=)
JP (2) JP2022521390A (https=)
CN (1) CN113424065A (https=)
BR (1) BR112021016597A2 (https=)
CA (2) CA3295270A1 (https=)
WO (1) WO2020169819A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102750097B1 (ko) * 2024-07-29 2025-01-03 가천대학교 산학협력단 심혈관 시술 이후 환자의 합병증 예측 및 추적 관리 시스템 및 방법
WO2025110596A1 (ko) * 2023-11-23 2025-05-30 (의) 삼성의료재단 비심장 수술 후 심근 손상을 예측하기 위한 방법 및 장치
WO2025110595A1 (ko) * 2023-11-23 2025-05-30 (의) 삼성의료재단 비심장 수술 후 심장 트로포닌 수치를 예측하기 위한 방법 및 장치

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240221958A1 (en) * 2021-04-30 2024-07-04 Roche Diagnostics Operations, Inc. Pct marker panels for early detection of sepsis
WO2022229438A2 (en) * 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Il6 marker panels for early detection of sepsis
EP4351636A4 (en) * 2021-06-02 2025-04-23 Washington University Systems and methods for multimodal analysis of surgical drain fluid using interchangeable and customizable nucleic acid based tests
US12152280B2 (en) 2021-09-20 2024-11-26 Droplet Biosciences, Inc. Drain fluid for diagnostics
JP2023111774A (ja) * 2022-01-31 2023-08-10 国立研究開発法人国立循環器病研究センター 再灌流療法の適用を決定するバイオマーカー
WO2026013199A1 (en) 2024-07-12 2026-01-15 Cezanne S.A.S. Clinical immunoassay with early signal measurement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018151295A (ja) * 2017-03-14 2018-09-27 東ソー株式会社 全身状態の良不良を評価するための情報を提供する方法及び測定試薬
JP2020530123A (ja) * 2017-08-04 2020-10-15 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 真菌感染の診断及びリスク層別化

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
US4882733A (en) 1987-03-13 1989-11-21 Ford Aerospace Corporation Method and apparatus for combining encoding and modulation
FR2664699B1 (fr) 1990-07-13 1995-08-18 Cis Bio Int Procede d'amplification du signal d'emission d'un compose luminescent.
ATE312351T1 (de) 2004-02-13 2005-12-15 Brahms Ag Verfahren zur bestimmung der bildung von endothelinen zu zwecken der medizinischen diagnostik, sowie antikörper und kits für die durchführung eines solchen verfahrens
US9012151B2 (en) * 2006-11-09 2015-04-21 B.R.A.H.M.S. Gmbh Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin
DE102006060112A1 (de) * 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
JP5711131B2 (ja) * 2008-10-07 2015-04-30 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 最初の有害事象の予測のためのバイオマーカー
WO2014018464A1 (en) * 2012-07-23 2014-01-30 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of sepsis
GB201402293D0 (en) * 2014-02-11 2014-03-26 Secr Defence Biomarker signatures for the prediction of onset of sepsis
ES2944613T3 (es) * 2017-02-02 2023-06-22 Brahms Gmbh proADM y/o histonas como marcadores indicadores de un acontecimiento adverso

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018151295A (ja) * 2017-03-14 2018-09-27 東ソー株式会社 全身状態の良不良を評価するための情報を提供する方法及び測定試薬
JP2020530123A (ja) * 2017-08-04 2020-10-15 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 真菌感染の診断及びリスク層別化

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ENIKO EGYED: "Mid-regional proadrenomedullin (MR-proADM) in the assessment of postoperative risk for complications", BIOMARK GENE, vol. 1, no. 1, JPN6023048300, 8 March 2017 (2017-03-08), pages 1 - 8, ISSN: 0005204001 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025110596A1 (ko) * 2023-11-23 2025-05-30 (의) 삼성의료재단 비심장 수술 후 심근 손상을 예측하기 위한 방법 및 장치
KR20250077079A (ko) 2023-11-23 2025-05-30 (의) 삼성의료재단 비심장 수술 후 심근 손상을 예측하기 위한 방법 및 장치
WO2025110595A1 (ko) * 2023-11-23 2025-05-30 (의) 삼성의료재단 비심장 수술 후 심장 트로포닌 수치를 예측하기 위한 방법 및 장치
KR102750097B1 (ko) * 2024-07-29 2025-01-03 가천대학교 산학협력단 심혈관 시술 이후 환자의 합병증 예측 및 추적 관리 시스템 및 방법

Also Published As

Publication number Publication date
JP2025019061A (ja) 2025-02-06
CN113424065A (zh) 2021-09-21
BR112021016597A2 (pt) 2021-11-03
CA3126202A1 (en) 2020-08-27
CA3295270A1 (en) 2026-03-02
US20220187313A1 (en) 2022-06-16
WO2020169819A1 (en) 2020-08-27
EP3928099A1 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
JP2022521390A (ja) 術後有害事象の診断または予後
AU2021251382B2 (en) Pro-adrenomedullin for prognosing disease progression in severe acute respiratory syndrome (SARS)
JP2021508046A (ja) ｐｒｏ−ＡＤＭに基づく抗生物質療法の指導
JP2024023615A (ja) 感染性疾患の症状を有する患者において入院を必要とする病状のリスクを予測するためのｐｒｏ－ａｄｍ
US20250189539A1 (en) Sample including pro-adm as a therapy monitoring marker for critcally ill patients
JP2024009019A (ja) 併存症を有する患者におけるプロカルシトニンに基づく抗生物質療法のガイダンス
JP2023095851A (ja) 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ
RU2782305C2 (ru) Про-адм в качестве маркера мониторинга терапии для критически больных пациентов
RU2788885C2 (ru) Прокальцитонин и про-адм в качестве маркеров для мониторинга лечения антибиотиками
HK40077959A (en) Pro-adm for therapy monitoring of intensive care unit patients
HK40031519B (en) Pct and pro-adm as markers for monitoring antibiotic treatment
HK40030378B (zh) 基於pro-adm的抗生素疗法指导

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240617